Deals this week: Diffusion Pharmaceuticals, Celsion, Sailing Capital Overseas

9th February 2018 (Last Updated August 12th, 2019 10:39)

US-based clinical-stage biopharmaceutical company Diffusion Pharmaceuticals Inc plans to issue 12,262,447 shares of its common stock in a public offering.

US-based clinical-stage biopharmaceutical company Diffusion Pharmaceuticals Inc plans to issue 12,262,447 shares of its common stock in a public offering.

The shares will include 11,668,421 ordinary shares and 594,026 dividend shares and will be issued by the selling stockholders. Diffusion Pharmaceuticals selected Dechert LLP as legal advisor for the transaction.

Celsion Corp has issued shares of its common stock in a public offering to raise $10m.

The US-based oncology company plans to use funds for general corporate needs and for working capital.

Cantor Fitzgerald & Co was the underwriter, and Sidley Austin LLP was the legal advisor for the transaction.

Sailing Capital Overseas Investment Fund LP and partners have invested $30.6m in Cellular Biomedicine Group Inc.

Based in the US, Sailing Capital is a private equity firm, while Cellular Biomedicine is a development stage biomedicine company also based in the US.

The investment will enable Cellular Biomedicine to validate its proprietary technology platform and improve the prospects of approval from the China Food and Drug Administration (CFDA).

OncoQuest Inc has issued 603,000 shares priced at $10 a share in a private placement to raise $6.03m.

The company has also announced that existing shareholder Hepalink USA has agreed to exchange its entire preferred shares and 5% preferred share dividends into common shares. Hepalink USA will own 3,606,167 shares, following the transaction.

Based in Canada, OncoQuest is a biotechnology company and a subsidiary of Quest PharmaTech Inc. The company plans to use proceeds towards Phase II clinical trials on oregovomab and for general corporate needs.

Initiator Pharma AS plans to issue 8,683,941 shares priced at Skr2.20 ($0.28) each through a rights offering to raise Skr19.1m ($2.41m). The transaction is scheduled to be complete in March 2018.

The Denmark-based biotech company plans to use proceeds towards the clinical development of IPED2015.

"Underwriters will be granted a 30-day option to buy an additional 1.05 million shares."

The company has appointed Sedermera Fondkommission AB as financial advisor for the transaction.

Balmes Transplantation SAS has raised an additional funding of €700,000 ($870,000) in a seed funding round bringing the total proceeds raised to €1.6m ($2m).

The financing was provided by Patrick Berna (founder and CEO), Guillaume Demarne (CBDO) and a group of business angels.

Based in France, Balmes Transplantation is an early-stage pharmaceutical company.

The company plans to use proceeds for conducting proof-of-concept study to test its drug combination for kidney damage.

Ocunova LLC has raised $500,000 in a financing round led by Life Sciences Greenhouse of Central Pennsylvania (LSGCP) and Ben Franklin Technology Partners of Central and Northern Pennsylvania (BFTP).

Based in the US, Ocunova is developing a new therapeutic treatment for diabetic-related dry-eye syndrome.

The company plans to use proceeds for the development and clinical trials of a new product candidate for treatment of diabetic dry-eye syndrome (DES).

UK-based pharmaceutical company Acacia Pharma Group PLC plans to raise funds through an initial public offering (IPO).

The company plans to use proceeds to develop the sales and marketing infrastructure for the launch of BAREMSIS in early 2019.

Acacia Pharma has appointed Bank Degroof Petercam NV/SA and RBC Europe Limited as joint global coordinators for the transaction.

Miragen Therapeutics Inc plans to issue seven million underwritten shares of its common stock in a public offering.

Underwriters will be granted a 30-day option to buy an additional 1.05 million shares.

The US-based biopharmaceutical company intends to use proceeds for working capital and general corporate needs.

Miragen has appointed Evercore Group LLC, Jefferies LLC and Deutsche Bank Securities Inc as joint book-running managers and Cooley LLP as legal advisor for the transaction.